Vascular smooth muscle cell-related molecules and cells

Moyamoya Disease Update

Volumn , Issue , 2010, Pages 69-72

  Takagi, Yasushi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857901003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-99703-0_11     Document Type: Chapter

References (18)

1. Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056-1066
2. Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. N Engl J Med 360:1226-1237
3. Achrol AS, Guzman R, Lee M et al (2009) Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus 26:E4
4. Takagi Y, Kikuta K, Nozaki K et al (2007) Histological features of middle cerebral arteries from patients treated for moyamoya disease. Neurol Med Chir (Tokyo) 47:1-4
5. Aoyagi M, Fukai N, Yamamoto M et al (1996) Early development of intimal thickening in superficial temporal arteries in patients with moyamoya disease. Stroke 27:1750-1754
6. Soriano SG, Cowan DB, Proctor MR et al (2002) Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 50:544-549
7. Fujimura M, Watanabe M, Narisawa A et al (2009) Increased expression of serum matrix metalloproteinase-9 in patients with moyamoya disease. Surg Neurol [Epub ahead of print]
8. Yamamoto M, Aoyagi M, Fukai N et al (1999) Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease. Circ Res 85:912-918
9. Yamamoto M, Aoyagi M, Tajima S et al (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28:1733-1738
10. Nanba R, Kuroda S, Ishikawa T et al (2004) Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35:2837-2842
11. Houkin K, Yoshimoto T, Abe H et al (1998) Role of basic fibroblast growth factor in the pathogenesis of moyamoya disease. Neurosurg Focus 5:e2
12. Noda A, Suzuki Y, Takayasu M et al (2000) Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease. Acta Neurochir (Wien) 142:1275-1279
13. Aoyagi M, Fukai N, Matsushima Y et al (1993) Kinetics of 125I-PDGF binding and down-regulation of PDGF receptor in arterial smooth muscle cells derived from patients with moyamoya disease. J Cell Physiol 154:281-288
14. Yamamoto M, Aoyagi M, Fukai N et al (1998) Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with moyamoya disease. Stroke 29:1188-1193
15. Takagi Y, Kikuta K, Nozaki K et al (2007) Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with moyamoya disease. Neurosurgery 60:338-345
16. Hojo M, Hoshimaru M, Miyamoto S et al (1998) Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 89:623-629
17. Hoshimaru M, Takahashi JA, Kikuchi H et al (1991) Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study. J Neurosurg 75:267-270
18. Takagi Y, Kikuta K, Sadamasa N et al (2006) Caspase-3-dependent apoptosis in middle cerebral arteries in patients with moyamoya disease. Neurosurgery 59:894-900